Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
For more information, please contact:Investor Contact Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Tel: +49 (0)345 555 99 30 Email: IR@vivoryon.com ?
Media Contact Trophic Communications Valeria Fisher / Sophia Hergenhan Tel: +49 175 8041816 Email: firstname.lastname@example.org ?
About Vivoryon Therapeutics N.V. Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com ?
09.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: Vivoryon Therapeutics N.V. Weinbergweg 22 06120 Halle/Saale
Germany Phone: +49 (0)345 555 9900 Fax: +49 (0)345 555 9901 E-mail: email@example.com Internet: www.vivoryon.com ISIN: NL00150002Q7 WKN: A2QJV6 Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam EQS News ID: 1232472 ? End of News DGAP News Service